All In Biotech

Drug Trial Radar · NCT06893887

Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma

Exploratory Cohort Study and Mechanistic Research on Individualized Comprehensive Treatment After Standard Treatment for Advanced Hepatocellular Carcinoma

Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

270

Planned (sponsor's estimate)

Start

May 22, 2025

Primary completion

Dec 15, 2027

Study completion Dec 15, 2028

Sponsor

Lead sponsor
Nanjing Tianyinshan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This project is a prospective, multi-center, multi-cohort exploratory clinical study. It focuses on patients with advanced hepatocellular carcinoma who experience disease progression after first-line standard therapy. Based on different patterns of disease progression, patients will receive relevant systemic treatments, either with or without local interventional therapy. The primary endpoint is progression-free survival (PFS), while secondary endpoints include overall survival (OS), 1-year OS rate, objective response rate (ORR), disease control rate (DCR), duration of remission (DOR), and safety. Additionally, the study will explore the correlation between patients' clinical pathological characteristics, serum biomarkers, and clinical efficacy.

Conditions

  • Hepatocellular Carcinoma(HCC)

Interventions

  • FOLFOX4Drug

    FOLFOX4 was administered by oxaliplatin 85 mg/m² d1+ leucovorin 200 mg/m² d1-2+ fluorouracil 400 mg/m² 2 h→ 600 mg/m² 24 h d1-2 q2w, with a total of 4 cycles

  • AdebrelimabDrug

    Adebrelimab 1200mg, intravenous infusion, every 3 weeks

  • ApatinibDrug

    Apatinib 250mg, oral, once daily.

  • IcaritinDrug

    Epimedium extract soft capsules 2.4g, oral, 2 times daily.

  • Retlirafusp alfaDrug

    Retlirafusp alfa,1800mg, intravenous infusion, every 3 weeks, use for up to 2 years at most.

  • QL1706Drug

    QL1706,5mg/kg, intravenous infusion, every 3 weeks, use for up to 2 years at most.

  • BevacizumabDrug

    Bevacizumab 7.5mg, intravenous infusion, once every 3 weeks.

  • HAICProcedure

    Hepatic Arterial Infusion Chemotherapy

  • The original treatment regimenDrug

    Continue the original targeted therapy combined with immunotherapy. dosage, dosage form,frequency of administration was the same as before.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFS(Progression-free Survival)Time frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • China Pharmaceutical University Affiliated Nanjing Tianyinshan Hospital

    Nanjing, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.